Mangoceuticals enters consulting & amended services agreements with related party Epiq Scripts

MANGOCEUTICALS, INC.

Engaged Epiq Scripts for global pharmacy consulting outside US; $65K upfront plus per-pill declining fees over 5 years (amounts redacted).
Amended MSA: added right of first negotiation/refusal for new jurisdictions and a 1% non-use fee on gross sales if services transferred.
Epiq Scripts is 51% owned by CEO Jacob D. Cohen; the agreements are related-party transactions.
No consulting payments until first commercial sale outside US; no immediate revenue impact expected.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MANGOCEUTICALS, INC. entered into Consulting Agreement with Epiq Scripts, LLC (effective 2023-09-15).

Action: entry
Counterparty: Epiq Scripts, LLC
Effective: 2023-09-15

Exact text from the filing

On September 15, 2023, Mangoceuticals, Inc. (the " Company ", " we " and " us ") entered into (1) a Consulting Agreement (the " Consulting Agreement ") with Epiq Scripts, LLC (" Epiq Scripts ")

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MANGOCEUTICALS, INC. amended First Addendum to Master Services Agreement with Epiq Scripts, LLC (effective 2023-09-15).

Action: amendment
Counterparty: Epiq Scripts, LLC
Effective: 2023-09-15

Exact text from the filing

and (2) a First Addendum to Master Services Agreement with Epiq Scripts (the " First Amendment "), which amended that certain Master Services Agreement dated September 1, 2022, by and between the Company and Epiq Scripts (the " MSA ")

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

MANGOCEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-033356

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.